Cosmetics OEM PMD Act Checklist: Licenses, Labeling, and Claims Before Inquiry

In Japan, the manufacturer and the marketing authorization holder responsible for quality, labeling, and market release have different roles. When outsourcing to an OEM partner, first clarify who will be the responsible marketing authorization holder and what scope the supplier can cover.

A manufacturing license relates to the act of manufacturing, while marketing authorization relates to responsibility for placing the product on the market. Being able to manufacture a product is not the same as being responsible for labeling and quality assurance under the brand.

When inquiring, confirm cosmetics manufacturing license, cosmetics marketing authorization, responsibility for imported goods, full ingredient labeling, and handling of quality and product standard documents. If unsure, confirm with the authorization holder or a regulatory specialist.

In cosmetics OEM, labeling and advertising claims are as important as the formula. Decide who prepares and checks required information such as product name, category name, content volume, full ingredients, marketing authorization holder, usage precautions, and lot number.

Packaging, landing pages, and social ads should also be reviewed. Cosmetic claims are limited. Claims suggesting whitening, wrinkle improvement, hair growth, treatment, or strong improvement may fall into quasi-drug or drug territory.

If claims are corrected after design completion, boxes, labels, photos, and ads may need rework. Review desired claims, prohibited wording, and alternative wording alongside formula development.

Even within skincare, whether the product is developed as a cosmetic or a quasi-drug changes claims, ingredients, cost, and schedule significantly. Quasi-drug projects may require approval, notification, testing, and documents, often taking longer than ordinary cosmetics OEM.

If the brand wants to use claims such as whitening, wrinkle improvement, or hair growth, classification should be checked before formula development. Switching to quasi-drug later may require revising formula, container, labeling, ads, and launch timing.

First separate whether the product value is texture, scent, moisturizing feel, and brand world, or whether efficacy claims are central. If efficacy claims are important, consult the authorization holder or specialist early.

When inquiring, confirm not only the desired product image but also the supplier scope for PMD Act, labeling, and quality assurance. Ask whether they can act as authorization holder, whether the project uses an existing or new formula, whether they prepare full ingredient labels, and whether they check containers and labels.

Also ask about sample rounds, stability testing or patch testing policy, lot number management, and the contact flow for defects or skin complaints after delivery. Much of this is not visible from public information, so record responses and compare them.

Cosmetics carry responsibility after sale, not only production cost. Compare suppliers by quality assurance, labeling review, and claim-checking systems, not only price or MOQ.

Common risks include checking desired advertising claims too late, finalizing container or label design too early, and leaving product name or full ingredient labeling until the end. These can cause last-minute revisions and launch delays.

A safer workflow is to list desired claims at planning stage, check classification before formula development, and review label and package drafts during sampling. Before launch, review product pages, ads, and inserts as well.

This guide organizes practical check points and does not replace legal judgment. Product-specific decisions should be made with the marketing authorization holder, official information, and specialist confirmation.

Also confirm the contact point, lot traceability, and recall decision flow in case customer inquiries or skin issues occur after launch. In cosmetics OEM, supplier selection should include post-sale operations, not only pre-launch labeling review.